Can a smartphone app boost weight-loss drugs for obese teens?

NCT ID NCT06836284

Recruiting now Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a digital behavioral tool called Evira to standard obesity medication (liraglutide or semaglutide) helps teens with obesity lose more weight than medication alone. Forty adolescents aged 12-17 will be randomly assigned to either the combination or medication-only group and followed for six months. The main goal is to see if the digital tool improves weight loss and treatment adherence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liraglutide or semaglutide (obesity medication) plus a digital behavioral tool called Evira
What this could lead to: If it works, this could show that adding a digital behavioral tool to obesity medication helps teens lose more weight and stick with treatment better.
What could go wrong: This is a small, early-stage study with only 40 participants and a short 6-month follow-up. The digital tool may not provide extra benefit over medication alone, and results may not apply to all teens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENT OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder Pediatric Obesity Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD OBESITY TREATMENT ADHERENCE

Contacts and locations

Locations

HKH Crown Princess Victoria's Childrens and youth Hospital Linköping
RECRUITING

Linköping, Sweden
Ystad lasarett, Barn och ungdomsmedicinmottagningen
RECRUITING

Ystad, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.